Janney Montgomery Scott LLC Acquires 24,233 Shares of Bristol-Myers Squibb (NYSE:BMY)

Janney Montgomery Scott LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 2.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 978,960 shares of the biopharmaceutical company's stock after purchasing an additional 24,233 shares during the quarter. Janney Montgomery Scott LLC's holdings in Bristol-Myers Squibb were worth $59,707,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in BMY. Pinney & Scofield Inc. bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $26,000. Fairway Wealth LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at $28,000. Transce3nd LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $28,000. Finally, Global Wealth Strategies & Associates boosted its holdings in shares of Bristol-Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BMY shares. UBS Group decreased their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Argus raised Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Wall Street Zen lowered shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Jefferies Financial Group reduced their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Finally, Piper Sandler assumed coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Price Performance

BMY opened at $48.65 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The business has a fifty day moving average of $48.62 and a 200 day moving average of $54.63. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The stock has a market cap of $99.01 billion, a P/E ratio of -11.01, a PEG ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the prior year, the business posted ($4.40) earnings per share. The business's revenue for the quarter was down 5.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.